Company Grifols, S.A. OTC Markets

Company Grifols, S.A. OTC Markets

GIKLY

US3984382008

Pharmaceuticals

Analysts' Consensus

Equities

GIKLY

US3984382008

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Grifols, S.A.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Grifols, S.A.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Market Closed - OTC Markets Other stock markets 09:08:54 14/05/2024 pm IST			5-day change	1st Jan Change
5.46 ^USD	+3.80%		+6.64%	-37.24%

15/05	GRIFOLS : In line Q1 and on track deleveraging; worth a go
14/05	Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:

- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;

- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;

- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;

- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.

Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Number of employees: 23,744

EUR in Million	2022	Weight	2023	Weight	Delta
Biopharma 84.3 %	5,005	82.5 %	5,558	84.3 %	+11.05%
Diagnostic 10.2 %	671	11.1 %	670	10.2 %	-0.15%
Others 3.1 %	250	4.1 %	203	3.1 %	-18.67%
Bio Supplies 2.4 %	146	2.4 %	160	2.4 %	+9.50%

EUR in Million	2022	Weight	2023	Weight	Delta
United States and Canada 59.1 %	3,856	63.6 %	3,899	59.1 %	+1.12%
Rest of World 21.8 %	1,176	19.4 %	1,437	21.8 %	+22.19%
Rest of European Union 13.5 %	712	11.7 %	893	13.5 %	+25.50%
Spain 5.5 %	321	5.3 %	363	5.5 %	+13.18%

Managers	Title	Age	Since
Nacho Abia CEO	Chief Executive Officer	55	06/02
Alfredo Arroyo Guerra DFI	Director of Finance/CFO	67	01/07/01
Thomas Heinrich Glanzmann CHM	Chairman	65	05/06/05
Albert Coma-Cros CTO	Chief Tech/Sci/R&D Officer	-	01/04/01
Victor Grifols Deu BRD	Director/Board Member	48	30/16/30
Raimon Grifols Roura BRD	Director/Board Member	61	27/01/27
Tomás Dagá Gelabert BRD	Director/Board Member	68	13/00/13
Nuria Pascual Lapeña IRC	Investor Relations Contact	61	01/96/01
Fernando Sebastian Rodriguez Haro AUD	Comptroller/Controller/Auditor	45	01/16/01
Montserrat Gaja Llamas HRO	Human Resources Officer	58	01/21/01

Members of the board	Title	Age	Since
Thomas Heinrich Glanzmann CHM	Chairman	65	05/06/05
Tomás Dagá Gelabert BRD	Director/Board Member	68	13/00/13
Raimon Grifols Roura BRD	Director/Board Member	61	27/01/27
Íñigo Sánchez-Asiaín Mardones BRD	Director/Board Member	59	29/15/29
Carina Szpilka Lázaro BRD	Director/Board Member	56	29/15/29
James Costos BRD	Director/Board Member	61	09/20/09
Victor Grifols Deu BRD	Director/Board Member	48	30/16/30
Nacho Abia CEO	Chief Executive Officer	55	06/02
Enriqueta Felip Font BRD	Director/Board Member	59	24/19/24
Susana González Rodríguez BRD	Director/Board Member	47	10/22/10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	261,425,110	256,906,911 ( 98.27 %)	4,518,199 ( 1.728 %)	89.28 %
Stock B	1	426,129,798	356,937,772 ( 83.76 %)	3,944,430 ( 0.9256 %)

Name	Equities	%	Valuation
Grifols Roura Family 9.195 %	39,183,692	9.195 %	362 M $
Scranton Enterprises BV 8.404 %	35,812,622	8.404 %	331 M $
Grifols Gras Family 7.089 %	30,209,093	7.089 %	279 M $
Ralledor Holding Spain SL 6.154 %	26,224,374	6.154 %	242 M $
Capital Research & Management Co. (World Investors) 3.675 %	15,658,546	3.675 %	145 M $
BNP Paribas Asset Management Europe SAS 1.966 %	8,378,309	1.966 %	77 M $
Caixabank Asset Management SGIIC SA 1.340 %	5,710,858	1.340 %	53 M $
Rokos Capital Management LLP 1.137 %	4,843,786	1.137 %	45 M $
Melqart Asset Management (UK) Ltd. 1.124 %	4,790,811	1.124 %	44 M $
Bestinver Gestión SA SGIIC 0.8807 %	3,752,897	0.8807 %	35 M $

Name	Equities	%	Valuation
Brandes Investment Partners LP 5.156 %	13,480,174	5.156 %	87 M $
SIA Funds AG 0.2799 %	731,761	0.2799 %	5 M $
Devon Equity Management Ltd. 0.2618 %	684,481	0.2618 %	4 M $
Santander Private Banking Gestion SA SGIIC 0.2471 %	646,013	0.2471 %	4 M $
Cobas Asset Management SGIIC SA 0.2300 %	601,329	0.2300 %	4 M $
DNCA Finance SA 0.2054 %	536,996	0.2054 %	3 M $
Gescooperativo SA SGIIC 0.1699 %	444,201	0.1699 %	3 M $
GVC Gaesco Gestión SGIIC SA 0.1612 %	421,537	0.1612 %	3 M $
Popular Asset Management SGIIC SA 0.1575 %	411,639	0.1575 %	3 M $
Raiffeisen Kapitalanlage-Gesellschaft mbH 0.1530 %	400,000	0.1530 %	3 M $

Name	Equities	%	Valuation
Capital Research & Management Co. (World Investors) 7.937 %	20,749,225	7.937 %	130 M $
Millennium Management LLC 6.021 %	15,739,163	6.021 %	99 M $
Brandes Investment Partners LP 5.378 %	14,059,501	5.378 %	88 M $
Brandes Investment Partners LP 5.170 %	13,516,011	5.170 %	85 M $
Black Creek Investment Management, Inc. 3.539 %	9,251,618	3.539 %	58 M $
Flat Footed LLC 2.815 %	7,358,779	2.815 %	46 M $
Pictet Asset Management Holding SA 2.445 %	6,391,918	2.445 %	40 M $
Merrill Lynch International 1.610 %	4,207,933	1.610 %	26 M $
Whitebox Advisors LLC 1.407 %	3,678,262	1.407 %	23 M $
Morgan Stanley Capital Services LLC 1.143 %	2,989,145	1.143 %	19 M $

Name	Equities	%	Valuation
Yousif Capital Management LLC 0.001549 %	13,202	0.001549 %	57 178 $
DSM Capital Partners LLC 0.000481 %	4,096	0.000481 %	17 740 $

Name	Equities	%	Valuation
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. 6.49%	437,069,656	6.49%	433,358,935 $

Grifols SA

Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan

08174, Barcelona

+34 935 712 200

http://www.grifols.com

Name	Category and Sector
Gri-Cel SA Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The private company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk BÃ¼scher.	Financial Conglomerates
Grifols India Healthcare Pvt Ltd.
Squadron Reinsurance DAC Squadron Reinsurance DAC Multi-Line InsuranceFinance Part of Grifols SA, Squadron Reinsurance DAC is an Irish company that provides reinsurance services. The private company is based in Dublin, Ireland.	Multi-Line Insurance

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.18 EUR

Average target price

16.81 EUR

Spread / Average Target

+65.10%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
CSL LIMITED	-0.07%	91.42B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.08B
BIOGEN INC.	-9.06%	34.26B
UCB	+55.32%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-16.61%	15.27B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.42B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	9.16B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals